A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

This Phase 2 study is testing a drug called zanidatamab — a bispecific antibody that targets HER2-overexpressing tumors — in patients with advanced solid cancers (excluding biliary tract cancers) that have high HER2 protein expression. HER2 is a protein that drives some cancers to grow aggressively, and this drug is designed to block it from two angles simultaneously. **You may be eligible if...** - You are 18 or older - You have an advanced or metastatic solid tumor (not biliary tract cancer) that overexpresses HER2 (confirmed as IHC 3+ by a central lab) - Your cancer has progressed after at least one prior systemic treatment - If you have breast cancer or stomach/esophageal cancer, prior HER2-targeted therapy (including trastuzumab deruxtecan) is required - You have at least one measurable tumor and are in reasonably good physical condition (ECOG 0–1) **You may NOT be eligible if...** - Your cancer has not been confirmed as HER2 IHC 3+ by the designated lab - For Cohort 1 (non-breast/non-stomach cancers): you have had prior HER2-targeted therapy - You have unstable brain metastases - Your organ function or health status is insufficient to tolerate treatment - You have had prior HER2 ADC therapy (in certain cohorts) Talk to your doctor to see if this trial is right for you.